This article first appeared on GuruFocus.
Novartis AG (XSWX:NOVN) is set to release its Q1 2026 earnings on Apr 28, 2026. The consensus estimate for Q1 2026 revenue is $10.71 billion, and the earnings are expected to come in at $1.32 per share. The full year 2026’s revenue is expected to be $44.60 billion and the earnings are expected to be $5.72 per share. More detailed estimate data can be found on the Forecast page.
Revenue estimates for Novartis AG (XSWX:NOVN) have declined from $44.79 billion to $44.60 billion for the full year 2026 and increased from $46.69 billion to $46.94 billion for 2027 over the past 90 days. Earnings estimates have declined from $6.20 per share to $5.72 per share for the full year 2026 and from $6.79 per share to $6.42 per share for 2027 over the past 90 days.
Novartis AG (XSWX:NOVN) Reported History
In the previous quarter of 2025-12-31, Novartis AG’s (XSWX:NOVN) actual revenue was $10.46 billion, which missed analysts’ revenue expectations of $10.77 billion by -2.82%. Novartis AG’s (XSWX:NOVN) actual earnings were $0.98 per share, which missed analysts’ earnings expectations of $1.04 per share by -5.85%. After releasing the results, Novartis AG (XSWX:NOVN) was up by 1.56% in one day.
Novartis AG (XSWX:NOVN) 12 Month Price Targets
Based on the one-year price targets offered by 23 analysts, the average target price for Novartis AG (XSWX:NOVN) is $121.96 with a high estimate of $139.96 and a low estimate of $90.98. The average target implies an upside of 7.26% from the current price of $113.70.
Based on GuruFocus estimates, the estimated GF Value for Novartis AG (XSWX:NOVN) in one year is $102.76, suggesting a downside of -9.62% from the current price of $113.70.
Based on the consensus recommendation from 28 brokerage firms, Novartis AG’s (XSWX:NOVN) average brokerage recommendation is currently 2.6, indicating a “Hold” status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
